Contact Mammoth
Mammoth
3201 Stellhorn Road
Suite A-124
Fort Wayne, IN 46815
Ph: (800)618-2299
Mammoth Admin
Posted by Mammoth Admin
October 6, 2021

Mammoth Scientific Selects SS&C for Inaugural VC Fund

Innovative venture capital firm will leverage SS&C's fund administration services and Intralinks' InvestorVision for $100M fund

Mammoth Admin
Posted by Mammoth Admin
August 31, 2021

MiRus Receives FDA 510(K) Clearance For The Lowest Profile and Best-in-class Expandable Lumbar Interbody

MiRus LLC, the leading innovator in rhenium-based superalloy medical implants announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its IO™ Expandable Lumbar Interbody.

Mammoth Admin
Posted by Mammoth Admin
August 25, 2021

U.S. Venture Capital Firm backs MRIguidance

Mammoth Scientific invests $1.25 Million in MRIguidance through its venture capital fund Mammoth Private Capital to enable further growth and prepare for market roll-out of BoneMRI in the U.S.

Mammoth Admin
Posted by Mammoth Admin
August 20, 2021

InvestmentNews - Venture capital firm targets RIAs

High-net-worth clients are interested in private investments, and Mammoth Scientific, which just rolled out a $100 million venture capital fund, aims to provide such products to the RIA channel, say two of its founders, Jud Mackrill and Tommy Martin.

Mammoth Admin
Posted by Mammoth Admin
August 17, 2021

NIIC Member, Mammoth VC Launches 100M Fund

MiRus LLC, a commercial stage life sciences company, has completed a highly oversubscribed funding round for growth of its spine and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoRe®). The round was led by Mammoth Scientific and multi-generational family offices who have supported MiRus from its inception.

Mammoth Admin
Posted by Mammoth Admin
July 28, 2021

MiRus™ Raises $65 Million For Expansion of Rhenium-based Medical Devices

MiRus LLC, a commercial stage life sciences company, has completed a highly oversubscribed funding round for growth of its spine and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoRe®). The round was led by Mammoth Scientific and multi-generational family offices who have supported MiRus from its inception.


  • Mammoth Scientific is a venture capital company that specializes in health science and technology funds.
  • OFFICE ADDRESS
    3201 Stellhorn Road, Suite A-124
    Fort Wayne, IN 46815

    MAILING ADDRESS
    5651 Coventry Lane, Suite 306
    Fort Wayne, IN 46804
    (800)618-2299
  • OFFICES

    Atlanta
    Charleston
    Charlotte
    Fort Wayne
    Metro Detroit
  • Disclaimer

    The information provided on this mammoth.vc website ("Site") is provided to accredited and qualified investors to assist in evaluating the investment opportunity. The Site itself and the content on the Site are not offering documents. Any offer of securities related to Mammoth Health and Tech Fund 1- Accredited or Mammoth Health and Tech Fund 1- Qualified ("Mammoth Fund") may only be made by Mammoth Scientific, LLC as the Manager of the Mammoth Fund by delivery of definitive offering documents to the investor. Securities offered by Mammoth Scientific, LLC in the Mammoth Fund have not been registered under the Securities Act of 1933, as amended or the securities laws of any state or other jurisdictions in reliance upon exemptions from registration provided by the Securities Act and Regulation D Rules 506(c) and comparable exemptions. Mammoth Scientific, LLC is an investment advisor to certain venture capital funds including the Mammoth Fund. As an investment advisor to venture capital funds, Mammoth Scientific, LLC files as an exempt reporting advisor but that status does not imply a certain level of skill or training.

    PRIVATE COMPANIES AND PRIVATE INVESTMENTS INVOLVE UNIQUE RISKS. YOU SHOULD BE AWARE THAT WHEN INVESTING IN PRIVATE INVESTMENTS, YOU COULD LOSE YOUR ENTIRE INVESTMENT. WE RECOMMEND INVESTORS ONLY INVEST FUNDS WHICH THEY HAVE THE FINANCIAL CAPACITY TO LOSE.

    Mammoth Scientific, LLC and Mammoth Research, LLC are under common ownership and under common control at the board level as subsidiaries of Mammoth Investors, LLC, but not under common control at the day-to-day operating level. Ausdal Financial Partners, Inc. ("Ausdal"), 5187 Utica Ridge Rd, Davenport, IA 52807 (563)326-2064 (Member FINRA/SIPC) is acting as the Placement Agent for the Fund. Ausdal is independently owned and operated apart from the Mammoth entities. Investors should always consult the disclosure materials as these materials help investors to understand many of the risks involved with the particular investment which they are considering.

    All product names, logos, and brands are property of their respective owners in the U.S. and other countries, and are used for identification purposes only. Use of these names, logos, and brands does not imply affiliation or endorsement.

© 2021, Mammoth Investors, LLC
All rights reserved.
We use cookies to give you the best experience.

See How Mammoth Enables Wealth Managers to Access VC